Neuroendocrine Tumours

​Kjell Öberg is Professor of Endocrine Oncology at the Medical Faculty of Uppsala University and a former head of the Department of Endocrine Oncology, University Hospital, Uppsala. He is also Adjunct Professor of Surgery at Vanderbilt University, Nashville, Tenn., USA.  Dr. Öberg is a specialist in endocrinology and internal medicine with 40 years’ experience in the field of neuroendocrine tumors. He was one of the founders and coordinator of the European Neuroendocrine Tumor Network (ENET) (1995–2000), the president of ENETs 2010-2012 and is a past chairman of the Nordic Neuroendocrine Tumor Group. He has pioneered the treatment of carcinoid tumor patients with interferon and somatostatin analogs and developed assays for tumor markers such as chromogranin A and radiological procedures including specialized PET scans. Dr. Öberg has received numerous awards, including most recently the Rudbeck Medallion for excellence in research (2014), a Lifetime Achievement Awardfrom the North American Neuroendocrine Society (2014), The Swedish Endocrine Society Gold Medal for prominent research and clinical activities (2017), and a Lifetime Achievement Award from the European Neuroendocrine Tumor Society (ENETS), of which he has been Vice President since 2012.Suayib Yalcin is a medical oncologist with a special interest in gastrointestinal cancer treatment and research who is a full professor at Hacettepe University Cancer Institute, Turkey. Dr. Yalcin has served as Director of the Hacettepe University Oncology Hospital and Head of the Hacettepe University Medical Oncology Department. He has held a variety of important posts in medical organizations, including President of Turkish Society of Medical Oncology, General Secretary of Turkish Oncology Group, and National Representative of ESMO in Turkey. Currently he is President of the Turkish Association of Cancer Research and Control and President of Hacettepe Oncology Association.He is an active member of ASCO, ESMO, EORTC, and MMOF. Dr. Yalcin has participated in many clinical cancer research projects as a steering committee member or principal investigator and serves on the editorial board of several cancer journals. He has been the conference chair of the International Gastrointestinal Cancer Conference (www.igicc2017.org) for the past 7 years.  He has authored or co-authored more than 100 articles cited in Science Citation Index.

• 1. Introduction.- 2. Historical background.- 3. Epidemiology.- 4. Molecular biology.- 5. Genetic syndromes associated with NET.- 6. Pathological evaluation and Classification.- 7. Biomarkers.- 8. Radiological Imaging.- 9. Nuclear Imaging.- 10. Neuroendocrine Tumors of the Lung.- 11. Overview of Gastrointestinal NET.- 12. Overview of Pancreatic NET.- 13. Insulinoma.- 14. Gastrinoma.- 15. Vipoma and PPoma.- 16. Glucagonoma.- 17. Somatostatinoma.- 18. Less common types of pNET.- 19. Nonfunctional pNET.- 20. Poorly differentiated NET.- 21. Large cell NEC.- 22. MEN syndromes.- 23. Differentiated Thyroid cancer.- 24. Medullary thyroid cancer.- 25. Adrenocortical cancer.- 26. Paraganglioma, feokromostoma.- 27. Surgical Approach.- 28. Locoregional treatment (RFA) Embolization (Chemo/radio).- 29. PRRT.- 30. Management of hormonal symptoms.- 31. Carcinoid syndrome.- 32.Somatostatin analogues and interferon.- 33. Chemotherapy.- 34. Targeted therapies.- 35. Immunotherapy in the treatment of neuroendocrine tumors.- 36. Societies and guidelines.